Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WIN378 in Moderate to Severe Asthma
NCT07120503Phase 2Recruiting
- Sponsor
- Windward Bio
- Start
- Jul 2025
- Primary completion
- Oct 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing WIN378 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at Week 60, Treatment-Emergent Serious Adverse Events at Week 60 and 8 more. Started Jul 2025; status: recruiting.
02
Drugs
WIN378
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07120503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07120503.